Sage Journals: Discover world-class research

Open access

Research article

First published 2024

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment

Ema Kantorová, Marianna Vítková, Martina Martiníková [...]

Therapeutic Advances in Neurological Disorders

Open access

Research article

First published 2022-4

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Alasdair J Coles, Joanne L Jones, Patrick Vermersch [...]

Multiple Sclerosis Journal

Retricted access

Case report

First published 2020-1

Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis

Cinzia Valeria Russo, Francesco Saccà, Mariano Paternoster [...]

Multiple Sclerosis Journal

Retricted access

Article commentary

First published 2020-1

Clinical commentary on ‘Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis’

Stephen W Reddel

Multiple Sclerosis Journal

Free access

Research article

First published 2007-4

A New Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) for Alemtuzumab Determination: Development,Validation and Application

M. Montagna, M.A. Avanzini, L. Visai [...]

International Journal of Immunopathology and Pharmacology

Open access

Research article

First published 2019-8

Incidence,management,and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

Richard Phelps, Jonathan A Winston, Daniel Wynn [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2017-9

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

Rafael Arroyo González, Mariko Kita, Heidi Crayton [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2016-8

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

MD Willis, KE Harding, TP Pickersgill [...]

Multiple Sclerosis Journal

Search results